Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.

Snegha Ananth^1,2, Neha Agarwal¹, Bita Sahaf¹, Allison Jacob³, Lik Wee Lee³, Heidi Simmons³, Ilan Kirsch³, Sushma Bharadwaj¹, Wen-Kai Weng¹, Melody Smith¹, Saurabh Dahiya¹, David Miklos¹, Matthew J Frank¹

¹Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA.

²University of Nebraska Medical Center, Omaha, Nebraska, USA.

³Adaptive Biotechnologies, Seattle, Washington, USA.

PubMed PMC DOI PDF

Abstract

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR-T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic b…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.